Endpoints
death
DISEASE, AML
The primary endpoint of both studies was OS, defined as time from randomization to death from any cause. Patients were not censored at HSCT as HSCT was part of the treatment plan, given that the patient was eligible. Secondary efficacy endpoints included response rates and time-to-treatment response (non-intensive study only). Disease response was evaluated using the 2017 ELN recommendations for diagnosis and management of AML in adults [